What are the potential risks and benefits?
This gene therapy may help to slow the progression of frontotemporal dementia with GRN genetic variants, but this is not guaranteed and there are risks to consider.
Benefits: If effective, this gene therapy may slow the clinical progression of FTD with GRN genetic variants. However, results cannot be guaranteed. If the effects wear off, participants may return to their previous treatments but will not be able to receive an additional dose of the gene therapy as part of this clinical trial. By participating, you will contribute valuable information that could help improve future treatment options for others with FTD with GRN genetic variants.
Risks: All clinical trials involve some level of risk, and individual risks may vary. People who participate in this clinical trial may not be eligible for other gene therapy clinical trials in the future. Researchers take every measure to ensure safety, but each clinical trial carries its own unique risks.
To learn more about the risks and benefits of participating, please email Jim Howley, Global Lead, Patient Advocacy and Engagement, at Prevail.Patients@lilly.com or talk to your healthcare team.